Q1 2020 Earnings Estimate for Amarin Co. plc Issued By Oppenheimer (NASDAQ:AMRN)

Share on StockTwits

Amarin Co. plc (NASDAQ:AMRN) – Analysts at Oppenheimer dropped their Q1 2020 earnings per share estimates for Amarin in a research note issued to investors on Wednesday, January 22nd. Oppenheimer analyst L. Gershell now anticipates that the biopharmaceutical company will post earnings of ($0.07) per share for the quarter, down from their previous estimate of ($0.06). Oppenheimer has a “Sell” rating and a $13.00 price objective on the stock.

Other analysts also recently issued reports about the stock. Svb Leerink increased their price target on shares of Amarin from $26.00 to $29.00 and gave the company an “outperform” rating in a report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $51.00 price target on shares of Amarin in a research report on Thursday, January 9th. Jefferies Financial Group restated a “buy” rating and set a $30.00 price objective on shares of Amarin in a research note on Tuesday, January 14th. Roth Capital reissued a “buy” rating and issued a $31.00 price objective on shares of Amarin in a report on Tuesday, December 3rd. Finally, TheStreet raised Amarin from a “d” rating to a “c-” rating in a report on Friday, November 15th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. Amarin has an average rating of “Hold” and an average target price of $27.62.

NASDAQ:AMRN opened at $20.76 on Friday. Amarin has a 1 year low of $13.76 and a 1 year high of $26.12. The firm’s fifty day simple moving average is $21.19 and its 200 day simple moving average is $18.42. The company has a current ratio of 3.69, a quick ratio of 3.45 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $7.44 billion, a PE ratio of -103.79 and a beta of 1.05.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.03. Amarin had a negative return on equity of 26.67% and a negative net margin of 17.42%. The firm had revenue of $112.40 million during the quarter, compared to analyst estimates of $110.04 million. During the same period last year, the company earned ($0.08) EPS. Amarin’s quarterly revenue was up 104.4% compared to the same quarter last year.

In related news, CEO John F. Thero sold 475,546 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $24.02, for a total value of $11,422,614.92. Also, CEO John F. Thero sold 274,454 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $20.91, for a total value of $5,738,833.14. Over the last ninety days, insiders sold 788,600 shares of company stock worth $18,088,620. 2.75% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pictet Asset Management Ltd. lifted its holdings in shares of Amarin by 31.0% during the third quarter. Pictet Asset Management Ltd. now owns 1,886,232 shares of the biopharmaceutical company’s stock valued at $28,595,000 after purchasing an additional 445,895 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Amarin by 28.9% during the second quarter. Morgan Stanley now owns 1,639,098 shares of the biopharmaceutical company’s stock valued at $31,782,000 after purchasing an additional 367,369 shares in the last quarter. California Public Employees Retirement System lifted its holdings in shares of Amarin by 40.9% during the third quarter. California Public Employees Retirement System now owns 568,906 shares of the biopharmaceutical company’s stock valued at $8,625,000 after purchasing an additional 165,125 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Amarin by 73.3% during the second quarter. Bank of America Corp DE now owns 404,748 shares of the biopharmaceutical company’s stock valued at $7,849,000 after purchasing an additional 171,136 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB lifted its holdings in shares of Amarin by 14.0% during the third quarter. Rhenman & Partners Asset Management AB now owns 400,000 shares of the biopharmaceutical company’s stock valued at $6,064,000 after purchasing an additional 49,200 shares in the last quarter. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Further Reading: How does a dividend reinvestment plan work?

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.